(Nasdaq: FEED) Lights Up Our Radar Behind 5 Explosive Potential Catalysts (Tiny Float)

The enteral feeding device market is projected to grow

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: FEED) Lights Up Our Radar Behind 5 Explosive Potential Catalysts (Tiny Float) *Click Here To Get Our Alerts Faster Via SMS* May 11th Dear Reader, The enteral feeding device market is projected to grow from $2.9Bn in 2025 to $4.4Bn by 2032, reflecting rising demand for safer, more precise care solutions. Within this expanding space, one emerging heal-th-care technology company has been spending time strengthening leadership, expanding clinical adoption, and advancing a focused intellectual property strategy. Entering 2026, it is building momentum around two proprietary platforms, one designed to improve navigation in enteral access and another targeting non-invasive therapeutic applications. Together, these platforms position the company to expand its clinical relevance while opening new pathways across hospital and treatment settings. And over the past 6-month stretch, this profile's chart has showed explosive potential for significant, triple-digit-sized runs in the short term.  Could these moves be possible because this profile's float is under 1Mn shares? Now, we're not saying another short term chart move is expected, but with multiple potential catalysts hitting the news wire in early 2026, plus this tiny float, our full focus is going to be on this Nasdaq idea Tuesday: ENvue Medical, Inc. (Nasdaq: FEED) ENvue Medical, Inc. is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. And based on multiple potential catalysts on our radar, (Nasdaq: FEED) is making its way to the top of our watchlist. Check them out: #1. A Tiny Float May Help Establish An Environment For Heightened Volatility Potential. #2. FEED Registers A Major Commercial Milestone With New 3-Year Renewal. #3. A 6-Month Chart History Depicts Explosive Behavior Over Short Term Periods. #4. The Company Adds Its 40th U.S. Hospital Customer (Serves More Than 300K People). #5. The Company Buffs Up Its IP Portfolio's Protection By Securing A USPTO Notice Of Allowance. But more on those in a second... How ENvue® Makes All The Difference The Company's patented technology combines highly accurate body map, smart feeding tubes with built in sensors and continuous visual guidance Minimizes Potentially Fatal Results - The ENvue multiple views and steering direction guides the clinician through the GI tract, signaling when the patient is at risk. Reduces The Need For X-Ray Confirmation - Clinical trials using the ENvue system demonstrated full alignment between postprocedural X-Ray and feeding tube tip positioning on ENvue Screen reducing the need for repeated X-ray confirmation. Accelerate Access To Nutrition Support - Rapidly done feeding tube placement with consistently accurate position, even to the small bowel, ensures that critically ill patients receive nutrition as soon as possible. The ENvue System The ENvue® feeding tube placement system utilizes the most advanced methods of navigation, integrated sensors and body mapping to provide safe and rapid feeding tube placement. ENvue Feeding Tube Responsive torqueability and pushability Built-in passive sensor, activated when entering electromagnetic waves field Post procedure position check without stylet re-insertion ENFit® compatible Electromagnetic Field Generator And Sensors Generate an external field that covers the patient’s thorax and GI tract Create personalized body map Provide the same accurate image even when the patient is moving during the procedure Intuitive Screen Display Multiple, simultaneous views Red arrow alerts of potential entrance to airway White directional arrow indicates tube direction Actual patient body contour displayed Sensor in tube’s distal tip displays tip position and indicates direction in real time with no lagging ENvue Benefits The ENvue technology is backed by clinical trials; usage in many hospitals in the US; FDA 510(k) cleared 1.) Patient Lower risk of lung placement Reduces the need for X-Ray, less radiation exposure Effective post pyloric feeding Shorten the time to initiate food delivery, reduce risk of malnutrition 2.) Staff Builds confidence when placing feeding tubes Supports accurate feeding tube insertions that avoid the lungs Enables post pyloric position to facilitate early enteral feeding in malnourished ICU patients Only one operator required Short learning curve, 24/7 customer support 3.) Hospital Reliable equipment that can be used across continuum of care Innovative approach to training builds staff confidence and acceptance Surface Acoustic Wave (SAW) Technology: A Non-Invasive Revolution While the ENvue System handles navigation, the company’s SAW technology platform addresses the aftermath of indwelling device use. UroShield and PainShield are not just accessories; they are disruptive therapeutic tools. SAW technology creates low-frequency ultrasonic waves that run along the surface of a catheter or a patch on the skin. In the case of UroShield, these waves create an "acoustic shield" that prevents bacteria from adhering to the catheter surface. This effectively stops the formation of biofilms, which are the primary cause of Catheter-Associated Urinary Tract Infections (CAUTIs). Clinical case series have shown a staggering 94% average reduction in CAUTIs and catheter blockages when using this technology. Bridging the Gap: From Hospital to Home Care The recent launch of over-the-counter (OTC) reusable ENFit syringes on January 14th, 2026, marks a strategic pivot toward the home heal-th-care sector. As hospital stays become shorter, the burden of care is shifting to the patient and their family. These syringes comply with global ISO 80369-3 standards, ensuring they cannot be accidentally connected to the wrong medical lines, a critical safety feature in a home setting.  By offering these without a prescription, ENvue Medical, Inc. (Nasdaq: FEED) is tapping into a recurring revenue model that supports patient continuity of care outside the clinical environment. Grab Report Sources And More Here: FEED Website. ----- And as we mentioned earlier, (Nasdaq: FEED) has multiple potential catalysts on our radar. Take a look: #1. FEED Potential Catalyst - A Tiny Float May Help Establish An Environment For Heightened Volatility Potential. According to info from the Yahoo Finance website, FEED has a tiny float. The website reports this profile to have roughly 860.38k shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If the company provides positive news during the first half of 2026, could it help provide a breakout spark when paired with this volatility potential? ----- #2. FEED Potential Catalyst - FEED Registers A Major Commercial Milestone With New 3-Year Renewal. ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Heal-th Systems in the U.S. Operating Over 90 Hospitals Renewed agreement provides streamlined access to ENvue equipment and supplies across a network of more than 90 hospitals in 17 states TYLER, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced a three-year purchasing agreement renewal with the Group Purchasing Organization (“GPO”) for one of the largest non-pro-fit heal-th systems in the United States, operating over 90 hospitals across 17 states. The renewal ensures that hospitals and care sites within the network can access the ENvue™ Navigation Platform through established contracting pathways, without the need for individual procurement processes at the facility level. Contracted access within a heal-th system of this scale represents a significant commercial infrastructure advantage. Rather than navigating facility-by-facility value analysis committee approvals - a process that can take months - any participating hospital within the network can move directly to adoption. The three-year term locks that position through 2028, providing ENvue with a long-duration contracting foundation across a large and geographically distributed hospital network. "This renewal is an important commercial milestone for ENvue. We believe that having established access within a network of more than 90 hospitals in the U.S. means our technology is one clinical decision away from adoption at any participating facility. It reflects confidence in our platform, removes a critical friction point for customers, and gives us a durable foundation from which to drive broader utilization across the network," stated Doron Besser, MD, Chief Executive Officer of ENvue Medical. ENvue Medical remains focused on converting contracted access into active adoption, expanding its installed base within large heal-th system networks, and building long-term recurring commercial relationships with leading heal-th-care institutions across the United States. Read the full article here. ----- #3. FEED Potential Catalyst - A 6-Month Chart History Depicts Explosive Behavior Over Short Term Periods. Take a look at FEED's 6-Month chart: Taking a look at the chart above, FEED has displayed the ability to make significant moves in short periods of time. Now, that's not to say another vertical chart move is going to happen, but take a look at these previous ones for yourself: #1. From a January 27th, 2026 low of $1.02, FEED surged to a January 30th, 2026 high of $6.09 (497+% move). #2. From a March 15th, 2026 low of $1.05, FEED hit a high of $2.89+ on March 25th, 2026 (175+% move). #3. Most recently, FEED has jumped from a May 5th, 2026 low of $1.11 to a high of $1.535 on May 8th, 2026 (38+% move). Like we said, explosive. ----- #4. FEED Potential Catalyst - The Company Adds Its 40th U.S. Hospital Customer (Serves More Than 300K People). ENvue Medical Announces 40th U.S. Hospital Customer with Addition of a Virginia Medical Center Affiliated with the Mayo Clinic Care Network Regional hospital transitions feeding tube procedures from interventional radiology to bedside nursing care using the ENvue™ Navigation Platform TYLER, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced that a Virginia-based, 255-bed non-pro-fit regional medical center affiliated with the Mayo Clinic Care Network is now using the ENvue™ Navigation Platform. The hospital is now performing feeding tube placement through a nursing-led bedside model, transitioning procedures from interventional radiology to trained clinical staff at the point of care. “The transition to a nursing-led bedside model reflects a growing focus on efficiency and patient-centered care across hospital systems,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “With ENvue, care teams can perform feeding tube placement at the bedside, shifting procedures from interventional radiology to trained nursing staff and supporting a more streamlined process that reduces reliance on resource-intensive departments while maintaining clinical precision.” The agreement marks ENvue’s 40th U.S. hospital customer. The Virginia-based medical center, serving more than 300,000 people, expands ENvue’s presence across regional heal-th systems. “We’re seeing growing demand for technologies that bring greater visibility and consistency to feeding tube placement,” said Marc Waldman, Vice President of Commercial at ENvue Medical. “Hospitals are looking for solutions that can be implemented across care teams, and we believe that real-time visualization helps support more standardized practices throughout the hospital.” ... Read the full article here. ----- #5. FEED Potential Catalyst - The Company Buffs Up Its IP Portfolio's Protection By Securing A USPTO Notice Of Allowance. ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology Patent Expands Company's Proprietary Surface Acoustic Wave Platform into Advanced Therapeutic Delivery Applications TYLER, Texas, May 08, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue," "ENvue Medical" or the "Company"), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/025,969, covering a novel drug delivery system utilizing the Company's proprietary surface acoustic wave (SAW) technology to enhance transdermal delivery of cannabinoid-based therapeutics. The allowed claims provide broad intellectual property protection across multiple components of the combined SAW ultrasound and cann-a-binoid transdermal delivery system, including transdermal patch configurations, portable SAW-generating platforms, and methods shown to produce synergistic enhancement in cannabinoid absorption through the skin compared to administration via the transdermal patch alone. ... "This Notice of Allowance validates a meaningful expansion of our SAW platform into an entirely new therapeutic category,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “We believe that the USPTO's recognition of the synergistic effect between our ultrasound technology and cann-a-binoid transdermal delivery, and its determination that this combination was non-obvious, reflects the depth and breadth of our intellectual property portfolio. We believe this positions ENvue favorably as interest in cannabinoid-based therapeutics continues to grow, and we look forward to exploring the strategic opportunities this patent creates for the Company." The Company believes this patent allowance further reinforces the value and versatility of its proprietary SAW technology platform and highlights the potential for future applications beyond its currently marketed products. Read the full article here. ----- (Nasdaq: FEED) Recap - These 5 Potential Catalysts Are On Our Radar #1. A Tiny Float May Help Establish An Environment For Heightened Volatility Potential. #2. FEED Registers A Major Commercial Milestone With New 3-Year Renewal. #3. A 6-Month Chart History Depicts Explosive Behavior Over Short Term Periods. #4. The Company Adds Its 40th U.S. Hospital Customer (Serves More Than 300K People). #5. The Company Buffs Up Its IP Portfolio's Protection By Securing A USPTO Notice Of Allowance. ----- We're officially initiating coverage on ENvue Medical, Inc. (Nasdaq: FEED). Be on the lookout for updates coming your way shortly. Talk again soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. ENvue Medical, Inc. (FEED:US) previously changed their company name and symbols from NanoVibronix Inc. (NAOV:US) Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 05/11/2026 and ending on 05/12/2026 to publicly disseminate information about (FEED:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid twenty thousand USD ("Funds"). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (FEED:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/feed-ugdqi/#details

Fierce Investor | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice